Krystal Biotech Inc

NASDAQ:KRYS  
59.35
+2.42 (+4.25%)
Products, Regulatory

Krystal Biotech Announces Publication Of Phase 1 And 2 Clinical Trial Of B-Vec Data In Nature Medicine

Published: 03/28/2022 15:24 GMT
Krystal Biotech Inc (KRYS) - Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (gem 1/2 Study) of Beremagene Geperpavec (b-vec) Data in Nature Medicine.
Krystal Biotech Inc - No Grade 2 Or Above B-vec-related Adverse Events, Vector Shedding, Or Systemic Drug Exposure Were Noted.
Krystal Biotech - Treatment With B-vec Showed Robust Functional Col7 Expression and Assembly Into Basement Membrane-associated Anchoring Fibrils.
Krystal Biotech Inc - Primary and Secondary Mechanistic and Clinical Endpoints Were Met in Phase 1 and 2 Study of B-vec.